
BioVenture VoiCes with Chris Garabedian
BiotechTVAudio
- Format:
- Podcast
- New episodes:
- Every two weeks
- Typical length:
- about 1 hour 10 minutes
- Latest episode:
About this show
Hosted by Chris Garabedian, meet the leading Voices in the BioVenture community and hear their insights and perspectives on the challenges and successes with VC investing.
Covers: biotech, venture capital, life sciences investing, healthcare investing, biopharma industry, startup funding, medical devices, precision oncology
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast features conversations with leading venture investors in biotech about the challenges and successes of backing companies. Recent episodes cover corporate venture investing with Sanofi Ventures' Jason Hafler and early biotech history with Third Rock Ventures' Bob Tepper.
Cosmos
Similar in subject
- Project Medtech
Both cover: medical devices, startup funding, venture capital - Cell & Gene: The Podcast
Both cover: biopharma industry, precision oncology - The Biotech Startups Podcast
Both cover: biotech, venture capital
Similar shows
Explore more
Episodes
Episode 52: Madrona's Matt McIlwain
· 1 hr 9 min
Matt McIlwain describes moving to Seattle and investing in tech during its boom starting in the 1990's, and how learnings and experiences from tech have focused his approach to investing in life sciences.
Not rated yetEpisode 51: Vianti Capital's Arjun Goyal
· 1 hr 5 min
With an immigrant upbringing that took him to Australia, where he practiced medicine, and the UK, where he went to graduate school, before coming to the U.S. for a startup he co-founded and Harvard Business School, Arjun Goyal describes learnings along the way. He discusses his extensive experience in the venture world, first at 5AM Ventures and then Vida Ventures, before more recently founding Vianti Capital.
Not rated yetEpisode 50: Third Rock Ventures' Bob Tepper
· 1 hr 4 min
the early days of the biotech sector before it was common, the founding of Third Rock Ventures, and the unique culture at Third Rock that has produced so many investors and company builders who have achieved great things in their careers.
Not rated yetEpisode 49: Sanofi Ventures' Jason Hafler
· 1 hr 5 min
Jason Hafler shares an overview of the corporate side of the venture world. He describes the unique value that he believes a corporate based VC can bring to the companies it invests in. Plus, his description of cases where investments might ultimately be a good fit for BD and/or M&A within the company, and why an investment might ultimately land at a different suitor.
Not rated yetEpisode 48: Blackstone's Kiran Reddy
· 1 hr 7 min
Blackstone's Senior Managing Director Kiran Reddy describes his early life and education, and the impact that patient care has had on his approach to investing. He describes notable investments in neuroscience, and a stop at Biogen, before returning to investing at Clarus, which was acquired by Blackstone. He recalls the unique opportunity he saw when a company with the resources of Blackstone decided to go big into life sciences.
Not rated yetEpisode 47: Ally Bridge's Andrew Lam
· 1 hr 5 min
Andrew Lam describes his career journey that started with a Doctor of Pharmacy education before working in industry, the investment world, back in industry, and then settling at Ally Bridge. He discusses the successful investments Ally Bridge has made in biotech, including in technologies like radiopharmaceuticals and ADCs, and the concept of being a bridge to China innovation.
Not rated yetEpisode 46: Catalys Pacific's BT Slingsby
· 59 min
BT Slingsby describes his education and career abroad, which ultimately led him to found and manage the largest life sciences VC firm in Japan, Catalys Pacific. He describes the dual role of taking assets from Japan and building companies around them internationally., and also in-licensing assets approved elsewhere and doing the clinical work in Japan to get them approved there. Plus, the story of the GHIT Fund, which is meant to bring Japanese innovation to neglected diseases around the world.
Not rated yetEpisode 45: Catalio Capital Management's George Petrocheilos
· 1 hr 9 min
George Petrocheilos describes going to school at Hopkins and the relationships formed there that would ultimately lead down the road to specializing in healthcare investing. He discusses starting in life sciences investing at Camden Partners, and then co-founding Catalio. Over a short period of time, keys to success have been empowering academics and entrepreneurs and expanding into multiple strategies.
Not rated yetEpisode 44: BainCapital's Adam Koppel
· 1 hr 12 min
Adam Koppel describes his career path, which included a stop at McKinsey, Biogen, and twice at Bain (where he is now). He descrbies the private equity model they have been on the leading edge of, and his take on where we are in the biotech cycle. Plus, the critical importance of mentors.
Not rated yetEpisode 43: Lightstone Venture's Mike Carusi
· 1 hr 7 min
Mike Carusi describes his early life and career, how gaining an appreciation for sales made an impression on him early on, and his philosophy of investing in medical devices - and the similarities and differences between that and investing in therapeutics.
Not rated yetEpisode 42: Nextech's Thilo Schroeder
· 1 hr 5 min
Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.
Not rated yetEpisode 41: Forbion's Nanna Lüneborg
· 1 hr 2 min
Nanna Luneborg discusses hear career and joining Forbion. She describes the firm's investment approach, and her experience with everything from seed, to private, and to public investing in life sciences. Plus, thoughts on China and AI in biotech.
Not rated yetEpisode 40: GV's Krishna Yeshwant
· 1 hr 19 min
He describes his well-rounded background of studying and working in both software in Silicon Valley and Medicine in Boston, and the start of GV. He describes a conservative start to investing at GV, but also today how Alphabet's scale and cash gives them the ability to ride cycles and make concentrated bets on companies the team has conviction on.
Not rated yetEpisode 39: SV Health Investors' Kate Bingham
· 1 hr 12 min
Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery Fund, being on the UK's Vaccine Taskforce during Covid, and more.
Not rated yetEpisode 38: Deerfield Management's Jason Fuller
· 1 hr 5 min
He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas that interest him today and how he thinks about AI.
Not rated yetEpisode 37: SR One's Simeon George
· 1 hr 6 min
Simeon George discusses his early days at SR One while it was part of GSK, and the transition to making the firm independent in 2020. Plus, the importance of peer-to-peer collaboration, and his how he thinks about investing in different indications and modalities.
Not rated yetEpisode 36: Sofinnova Invetments' Jim Healy
· 1 hr 1 min
He discusses learnings from his decades in venture at Sofinnova Investments including 'products vs platform', therapeutics areas of interest, modalities, and how he utilizes board seats and thinks about management teams.
Not rated yetEpisode 35: INITIATE Ventures' Jessica Owens
· 1 hr 9 min
Jessica Owens discusses the many experiences she has had in her career, including working on the venture side at Kleiner Perkins and Versant Ventures and on the operating side at Genomic Health and Grail. She highlights the value of VCs being able to understand how operators like CEOs think, and describes the type of investing INITIATE focuses on.
Not rated yetEpisode 34: General Atlantic's Brett Zbar
· 1 hr 7 min
Brett Zbar describes his early career, including working at Aisling Capital and Foresight Capital, and now managing the healthcare strategy at General Atlantic. He describes how he sees the difference between private equity and venture capital, and discusses which themes in biotech and healthcare appeal to him today.
Not rated yetEpisode 33: Pappas Capital's Art Pappas
· 58 min
Art Pappas describes his early career, which involved numerous overseas posts for large companies, and how it let him to eventually found Pappas Capital. He discusses the various ways the firm invests, and how having corporates partners as LPs and co-investors has been a recipe for success.
Not rated yet